PCN113 COST-MINIMISATION AND FIVE-YEAR BUDGET IMPACT ANALYSIS FOR MVASI® (BEVACIZUMAB BIOSIMILAR) IN ITALY

Abstract

To analyse with a cost minimisation analysis (CMA) the per-patient costs and potential savings of MVASI® (bevacizumab biosimilar) compared with originator Avastin® in all reimbursed indications in Italy and to estimate with a budget impact analysis (BIA) the consequences of bevacizumab biosimilar introduction over the next 5 years. In both analyses, only drug costs were included as no differences in administration costs are expected between treatment. Official, public drug prices were used for Avastin®, and a mandatory flat 20% discount was applied for MVASI®. The budget impact analysis was based on bevacizumab expenditure in Italy in 2017 derived from the Italian pharmaceutical expenditure report. Uptake of bevacizumab biosimilars and market shares of biosimilars were based on the case history of rituximab biosimilars. A deterministic sensitivity analysis (DSA) was conducted to complement the budget impact estimates. MVASI® was shown to generate savings ranging from €5.797 (in metastatic colorectal cancer) to €11.595 (in advanced or metastatic renal cell cancer) per patient per year vs. Avastin. The BIA of introducing bevacizumab biosimilars in Italy could generate savings of 145.4 million euros over the next 5 years. The DSA demonstrated that the drivers of savings are the total bevacizumab market use in Year 5 and the biosimilar uptake rate in Year 5. With an increasing discount over time, savings through the adoption of bevacizumab biosimilars will be much higher. The CMA demonstrated that substantial savings can be achieved with the adoption of MVASI®. The BIA showed that the introduction of bevacizumab biosimilars may produce major cost savings using a conservative fixed 20% discount for biosimilars over a five-year time horizon. This confirms the importance of a successful biosimilar adoption which could potentially provide additional resources to fund innovative treatments that can improve patient care.